Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes

Exenatide once weekly (EQW), the first glucose-lowering agent for type 2 diabetes that is dosed one time per week, contains exenatide encapsulated in microspheres of a dissolvable matrix, which release active agent slowly and continuously into the circulation following subcutaneous injection. In two...

Descripción completa

Detalles Bibliográficos
Autores principales: Stolar, Mark W, Grimm, Michael, Chen, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840776/
https://www.ncbi.nlm.nih.gov/pubmed/24285927
http://dx.doi.org/10.2147/DMSO.S48837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840776/
https://www.ncbi.nlm.nih.gov/pubmed/24285927
http://dx.doi.org/10.2147/DMSO.S48837

Ejemplares similares